SCHEMBL18949633

SCHEMBL18949633

COc1ccc(Cl)c(-c2ccc(OC)c(Cl)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.49
PTGS1 P23219 2/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2E1 P05181 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP4B1 P13584 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP3A5 P20815 1/20 0.46
CYP2A7 P20853 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7777278 0.83 HSP90AA1 (0.50) CA12CA1CA2CA7CA9
SCHEMBL12603887 0.82 TAS1R3 (0.49) PTGS2PTGS1CA12CA1CA2
SCHEMBL29587997 0.81 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL197088 0.81 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL6002589 0.79 CA12 (0.60) CA12CA1CA2CA7CA9
SCHEMBL19785375 0.79 HSP90AA1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL12326172 0.79 PTGS2 (0.53) PTGS2PTGS1CYP3A4ALDH1A1HSD17B10
SCHEMBL28866454 0.79 CYP1A1 (0.53) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
Nitrogen SCHEMBL11366394 0.77 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL1337556 0.77 HSP90AA1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2021-07-15 US disclosed
US-9676721-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2017-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD PTGS2 1251/4885PTGS1 897/4885CA12 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.